1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Drug-Eluting Stents Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Coating
6.1 Polymer Based Coating
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Polymer Free Coating
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Drug
7.1 Sirolimus
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Paclitaxel
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Zotarolimus
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Everolimus
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Biolimus
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 Market Breakup by Stent Platform
8.1 Stainless-steel
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Cobalt-Chromium
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Platinum-Chromium
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Nitinol
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Generation
9.1 1st Generation
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 2nd Generation
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 3rd Generation
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 4th Generation
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by Application
10.1 Coronary Artery Disease
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Peripheral Artery Disease
10.2.1 Market Trends
10.2.2 Market Forecast
11 Market Breakup by End User
11.1 Hospitals
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Ambulatory Surgical Centers
11.2.1 Market Trends
11.2.2 Market Forecast
11.3 Others
11.3.1 Market Trends
11.3.2 Market Forecast
12 Market Breakup by Region
12.1 North America
12.1.1 United States
12.1.1.1 Market Trends
12.1.1.2 Market Forecast
12.1.2 Canada
12.1.2.1 Market Trends
12.1.2.2 Market Forecast
12.2 Asia-Pacific
12.2.1 China
12.2.1.1 Market Trends
12.2.1.2 Market Forecast
12.2.2 Japan
12.2.2.1 Market Trends
12.2.2.2 Market Forecast
12.2.3 India
12.2.3.1 Market Trends
12.2.3.2 Market Forecast
12.2.4 South Korea
12.2.4.1 Market Trends
12.2.4.2 Market Forecast
12.2.5 Australia
12.2.5.1 Market Trends
12.2.5.2 Market Forecast
12.2.6 Indonesia
12.2.6.1 Market Trends
12.2.6.2 Market Forecast
12.2.7 Others
12.2.7.1 Market Trends
12.2.7.2 Market Forecast
12.3 Europe
12.3.1 Germany
12.3.1.1 Market Trends
12.3.1.2 Market Forecast
12.3.2 France
12.3.2.1 Market Trends
12.3.2.2 Market Forecast
12.3.3 United Kingdom
12.3.3.1 Market Trends
12.3.3.2 Market Forecast
12.3.4 Italy
12.3.4.1 Market Trends
12.3.4.2 Market Forecast
12.3.5 Spain
12.3.5.1 Market Trends
12.3.5.2 Market Forecast
12.3.6 Russia
12.3.6.1 Market Trends
12.3.6.2 Market Forecast
12.3.7 Others
12.3.7.1 Market Trends
12.3.7.2 Market Forecast
12.4 Latin America
12.4.1 Brazil
12.4.1.1 Market Trends
12.4.1.2 Market Forecast
12.4.2 Mexico
12.4.2.1 Market Trends
12.4.2.2 Market Forecast
12.4.3 Others
12.4.3.1 Market Trends
12.4.3.2 Market Forecast
12.5 Middle East and Africa
12.5.1 Market Trends
12.5.2 Market Breakup by Country
12.5.3 Market Forecast
13 SWOT Analysis
13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats
14 Value Chain Analysis
15 Porters Five Forces Analysis
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes
16 Price Analysis
17 Competitive Landscape
17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
17.3.1 Abbott Laboratories
17.3.1.1 Company Overview
17.3.1.2 Product Portfolio
17.3.1.3 Financials
17.3.1.4 SWOT Analysis
17.3.2 B. Braun Melsungen AG
17.3.2.1 Company Overview
17.3.2.2 Product Portfolio
17.3.2.3 SWOT Analysis
17.3.3 Biosensors International Group Ltd.
17.3.3.1 Company Overview
17.3.3.2 Product Portfolio
17.3.4 Biotronik
17.3.4.1 Company Overview
17.3.4.2 Product Portfolio
17.3.4.3 SWOT Analysis
17.3.5 Boston Scientific Corporation
17.3.5.1 Company Overview
17.3.5.2 Product Portfolio
17.3.5.3 Financials
17.3.5.4 SWOT Analysis
17.3.6 Cardinal Health Inc.
17.3.6.1 Company Overview
17.3.6.2 Product Portfolio
17.3.6.3 Financials
17.3.6.4 SWOT Analysis
17.3.7 Cook Medical LLC (Cook Group Incorporated)
17.3.7.1 Company Overview
17.3.7.2 Product Portfolio
17.3.7.3 SWOT Analysis
17.3.8 Lepu Medical Technology (Beijing) Co. Ltd.
17.3.8.1 Company Overview
17.3.8.2 Product Portfolio
17.3.8.3 Financials
17.3.9 Medtronic plc
17.3.9.1 Company Overview
17.3.9.2 Product Portfolio
17.3.9.3 Financials
17.3.9.4 SWOT Analysis
17.3.10 MicroPort Scientific Corporation
17.3.10.1 Company Overview
17.3.10.2 Product Portfolio
17.3.11 Sino Medical Sciences Technology Inc.
17.3.11.1 Company Overview
17.3.11.2 Product Portfolio
17.3.12 Terumo Corporation
17.3.12.1 Company Overview
17.3.12.2 Product Portfolio
17.3.12.3 Financials
17.3.12.4 SWOT Analysis
世界の薬剤溶出性ステント市場予測2023年-2028年 |
| 【英語タイトル】Drug-Eluting Stents Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 | |
 | ・商品コード：IMARC23FB0047 ・発行会社（調査会社）：IMARC ・発行日：2023年2月1日 ・ページ数：148 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール ・調査対象地域：グローバル ・産業分野：医療 |
| Single User | USD2,999 ⇒換算￥455,848 | 見積依頼/購入/質問フォーム |
| Five User | USD3,999 ⇒換算￥607,848 | 見積依頼/購入/質問フォーム |
| Enterprisewide | USD4,999 ⇒換算￥759,848 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| IMARC社の本調査レポートによると、2022年に7.8億ドルであった世界の薬剤溶出性ステント市場規模が、2028年までに11.4億ドルに拡大し、予測期間中にCAGR6.31%で成長する見込みです。本書では、薬剤溶出性ステントの世界市場を調査・分析し、市場の実態を明らかにしており、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、コーティング別（ポリマー型コーティング、非ポリマー型コーティング）分析、薬剤別（シロリムス、パクリタキセル、ゾタロリムス、エベロリムス、その他）分析、ステントプラットフォーム別（ステンレススチール、コバルト-クロム、プラチナ-クロム、ニチノール、その他）分析、世代別（第1世代、第2世代、第3世代、第4世代）分析、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ）、SWOT分析、バリューチェーン分析、ポーターズファイブフォース分析、価格分析、競争状況などの項目が掲載されています。また、本書には、Abbott Laboratories、B. Braun Melsungen AG、Biosensors International Group Ltd.、Biotronik、Boston Scientific Corporation、Cardinal Health Inc.、Cook Medical LLC (Cook Group Incorporated)、Lepu Medical Technology (Beijing) Co. Ltd.、Medtronic plcなどの企業情報が含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界の薬剤溶出性ステント市場規模：コーティング別 - ポリマー型コーティングにおける市場規模 - 非ポリマー型コーティングにおける市場規模 ・世界の薬剤溶出性ステント市場規模：薬剤別 - シロリムスの市場規模 - パクリタキセルの市場規模 - ゾタロリムスの市場規模 - エベロリムスの市場規模 - その他の市場規模 ・世界の薬剤溶出性ステント市場規模：ステントプラットフォーム別 - ステンレススチールにおける市場規模 - コバルト-クロムにおける市場規模 - プラチナ-クロムにおける市場規模 - ニチノールにおける市場規模 - その他における市場規模 ・世界の薬剤溶出性ステント市場規模：世代別 - 第1世代薬剤溶出性ステントの市場規模 - 第2世代薬剤溶出性ステントの市場規模 - 第3世代薬剤溶出性ステントの市場規模 - 第4世代薬剤溶出性ステントの市場規模 ・世界の薬剤溶出性ステント市場規模：地域別 - 北米の薬剤溶出性ステント市場規模 - アジア太平洋の薬剤溶出性ステント市場規模 - ヨーロッパの薬剤溶出性ステント市場規模 - 中南米の薬剤溶出性ステント市場規模 - 中東・アフリカの薬剤溶出性ステント市場規模 ・SWOT分析 ・バリューチェーン分析 ・ポーターズファイブフォース分析 ・価格分析 ・競争状況 |
The global drug-eluting stents market size reached US$ 7.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 11.4 Billion by 2028, exhibiting a growth rate (CAGR) of 6.31% during 2023-2028.
A drug-eluting stent (DES) is a coronary device that is used for the slow release of drugs in peripheral or coronary arteries to block cell proliferation and promote a healthy flow of blood. It consists of a metallic stent, polymer coating and anti-restenosis drug. The stent is coated with medications that assist the arteries to remain smooth and ensure adequate blood flow. DES is widely used to treat blockages in heart arteries, prevent plaque buildup, blood clots and reduce repeated revascularization. The stent is minimally invasive (MI) and offers lower restenosis rates, enhanced vessel healing and reduced need for prolonged dual antiplatelet therapy.
Drug-Eluting Stents Market Trends:
The rising geriatric population prone to chronic medical ailments is one of the key factors driving the growth of the market. DES is widely utilized in patients with a high risk of developing arterial disorders as the stents aid in reducing the need for invasive procedures, such as coronary artery bypass surgeries. Additionally, the increasing prevalence of cardiovascular diseases due to the unhealthy dietary patterns, lack of physical activity and sedentary lifestyles of the masses is favoring the market growth. Moreover, various technological advancements, such as the launch of bioresorbable stents, are providing a thrust to the market growth. These stents are easily dissolvable in the body and reduce the risk of developing stent thrombosis. In line with this, the widespread adoption of stents with polymer-free coatings is positively impacting the market growth. These stents exhibit a higher drug loading capacity and quicker drug-eluting rate. Other factors, including the rising incidence of abnormal heart rhythms, heart failure and heart attack disease, along with the increasing demand for MI techniques among the masses, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global drug-eluting stents market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on coating, drug, stent platform, generation, application and end user.
Breakup by Coating:
Polymer Based Coating
Polymer Free Coating
Breakup by Drug:
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
Breakup by Stent Platform:
Stainless-steel
Cobalt-Chromium
Platinum-Chromium
Nitinol
Others
Breakup by Generation:
1st Generation
2nd Generation
3rd Generation
4th Generation
Breakup by Application:
Coronary Artery Disease
Peripheral Artery Disease
Breakup by End User:
Hospitals
Ambulatory Surgical Centers
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Group Ltd., Biotronik, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical LLC (Cook Group Incorporated), Lepu Medical Technology (Beijing) Co. Ltd., Medtronic plc, MicroPort Scientific Corporation, Sino Medical Sciences Technology Inc. and Terumo Corporation.
Key Questions Answered in This Report
1. What was the size of the global drug-eluting stents market in 2022?
2. What is the expected growth rate of the global drug-eluting stents market during 2023-2028?
3. What are the key factors driving the global drug-eluting stents market?
4. What has been the impact of COVID-19 on the global drug-eluting stents market?
5. What is the breakup of the global drug-eluting stents market based on the coating?
6. What is the breakup of the global drug-eluting stents market based on the stent platform?
7. What is the breakup of the global drug-eluting stents market based on the application?
8. What is the breakup of the global drug-eluting stents market based on the end user?
9. What are the key regions in the global drug-eluting stents market?
10. Who are the key players/companies in the global drug-eluting stents market?
❖ レポートの目次 ❖
| ★調査レポート[世界の薬剤溶出性ステント市場予測2023年-2028年] (コード：IMARC23FB0047)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の薬剤溶出性ステント市場予測2023年-2028年]についてメールでお問い合わせ |
